Cannabinoid modulation of microglial response to the HIV protein Tat

描述（由申请方提供）：本项目的目的是确定外源性大麻素在调节小胶质细胞对人类免疫缺陷病毒-1（HIV-1）反式激活（达特）蛋白的反应性方面的功能相关性。小胶质细胞是中枢神经系统（CNS）的常驻巨噬细胞，其充当HIV-1的主要靶标。这些细胞是HIV-1的生产宿主，并在感染后引发过多的细胞因子，单核因子和神经毒性因子。其中包括病毒包膜糖蛋白gp 120和病毒特异性基因产物达特。虽然这两种蛋白质都可以激活CNS中未感染的小胶质细胞和免疫细胞，导致炎性和神经毒性因子的大量释放，但HIV感染细胞产生达特不受目前可用的抗逆转录病毒药物的影响，因为这些药物靶向HIV的逆转录酶和蛋白酶。该观察结果与达特在细胞外释放的事实一起，阐明了在当前高效抗逆转录病毒治疗时代评估其在HIV神经发病机制中的作用的基本原理。达特发挥强大的趋化特性，并可能招募未感染的小胶质细胞和其他免疫细胞到HIV-1感染的焦点区域。趋化性驱动的免疫细胞聚集在感染的焦点区域和炎症因子的诱发的联合作用可能是HIV相关的神经认知障碍（HAND）的发展中的主要促成因素。大麻素已被证明可以调节免疫细胞的功能活动，包括小胶质细胞的功能活动。这些作用的优势是抑制性的，并通过CB 2大麻素受体（CB 2 R）介导。由于该受体在神经炎症的各种状态期间由小胶质细胞表达，因此其具有充当用于消除不利免疫应答（包括由达特引起的免疫应答）的细胞选择性分子靶标的潜力。因此，CB 2 R可以作为模板，用于生成缺乏精神药物特性的特定配体，并基于与它们相互作用的受体的关键特征进行合理设计。在拟议的研究中，我们将测试的假设，选择外源性大麻素通过CB 2 R，并可能其他大麻素受体，抑制小胶质细胞炎症反应达特。以下具体目标将作为研究的指导方针：（1）确定外源性大麻素对人小胶质细胞对HIV蛋白达特的反应性的体外作用，（2）建立外源性大麻素改变小胶质细胞对HIV蛋白达特的反应性的作用模式，以及（3）在人混合胶质细胞培养物和小鼠脑切片培养物的背景下，建立外源性大麻素对小胶质细胞对达特的反应性的影响的相关性。

DESCRIPTION (provided by applicant): The goal of this project is to establish the functional relevance of exogenous cannabinoids in modulating responsiveness of microglia to the human immunodeficiency virus-1 (HIV-1) trans-activating (Tat) protein. Microglia are resident macrophages of the central nervous system (CNS) that serve as principal targets for HIV-1. These cells are productive hosts for HIV-1 and elicit a plethora of cytokines, monokines, and neurotoxic factors in response to infection. Included among these are the virus envelope glycoprotein gp120 and the virus-specified gene product Tat. While both proteins can activate uninfected microglia and immunocytes in the CNS resulting in an expansive release of inflammatory and neurotoxic factors, the production of Tat by HIV- infected cells is not affected by currently available anti-retroviral drugs since these target the reverse transcriptase and protease enzymes of HIV. This observation, taken together with the fact that Tat is released extracellularly, articulates a rationale for assessment of its role in HIV neuropathogenesis in the current highly- active antiretroviral therapy era. Tat exerts robust chemotactic properties and may recruit uninfected microglia and other immunocytes to focal areas of HIV-1 infection. The combined action of chemotaxis-driven aggregation of immunocytes at focal areas of infection and elicitation of inflammatory factors may be a major contributive factor in the development of HIV-associated neurocognitive disorder (HAND). Cannabinoids have been shown to modulate the functional activities of immune cells, including those of microglia. The preponderance of these effects has been inhibitory and mediated through the CB2 cannabinoid receptor (CB2R). Since this receptor is expressed by microglia during various states of neuroinflammation, it has the potential to serve as a cell-selective molecular target for ablating untoward immune responses, including those engendered by Tat. Thus, the CB2R may serve as a template for the generation of specific ligands devoid of psychotropic properties and rationally designed based on the critical features of the receptors with which they interact. In the proposed study we will test the hypothesis that select exogenous cannabinoids act through the CB2R, and possibly other cannabinoid receptors, to dampen microglial inflammatory responses to Tat. The following specific aims will serve as guidelines to the research: (1) to define the in vitro effects of exogenous cannabinoids on human microglial responsiveness to the HIV protein Tat, (2) to establish the mode of action through which exogenous cannabinoid alters microglial responsiveness to the HIV protein Tat, and (3) to establish the relevance of the effects of exogenous cannabinoid on microglial responsiveness to Tat in the context of human mixed glial cultures and mouse brain slice cultures.